Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
Jesús San-MiguelBinod DhakalKwee YongAndrew SpencerSébastien AnguilleMaría-Victoria MateosCarlos Fernández de LarreaJoaquín Martínez-LópezPhilippe MoreauCyrille TouzeauXavier LeleuIrit AviviMichele CavoTadao IshidaSeok Jin KimWilfried RoeloffzenNiels W C J van de DonkDominik DytfeldSurbhi SidanaLuciano José Megale CostaAlbert OriolRakesh PopatAbdullah M KhanYaël C CohenP Joy HoJames GriffinNikoletta LendvaiCarolina LonardiAna SlaughterJordan M SchecterCarolyn C JacksonKaitlyn ConnorsKatherine LiEnrique ZudaireDiana ChenJane GilbertTzu-Min YehSarah NagleErika FlorendoLida PacaudNitin PatelSimon J HarrisonHermann EinselePublished in: The New England journal of medicine (2023)
A single cilta-cel infusion resulted in a lower risk of disease progression or death than standard care in lenalidomide-refractory patients with multiple myeloma who had received one to three previous therapies. (Funded by Janssen and Legend Biotech; CARTITUDE-4 ClinicalTrials.gov number, NCT04181827.).